Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
- 19 September 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (12), 1103-1113
- https://doi.org/10.1056/nejmoa1904143
Abstract
There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.Keywords
Funding Information
- Japan Cardiovascular Research Foundation
This publication has 19 references indexed in Scilit:
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationThe New England Journal of Medicine, 2019
- Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic TherapyCirculation, 2019
- 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillationHeart Rhythm, 2019
- 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet TherapyCanadian Journal of Cardiology, 2017
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationThe New England Journal of Medicine, 2017
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIThe New England Journal of Medicine, 2016
- Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCirculation: Cardiovascular Interventions, 2016
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingThe New England Journal of Medicine, 1998